InfuSystem Announces Financial Results for Third Quarter 2026

What happened

InfuSystem reported third-quarter 2026 revenue of $37.6 million, up 3.0% from a year earlier. Patient Services revenue rose 15% to $25.8 million, while Device Solutions revenue fell 17% to $11.8 million. Net income increased to $3.2 million, or $0.15 per diluted share.

Confirmed

Global impact / market context

Growth was concentrated in Patient Services, while Device Solutions contracted, showing that the two businesses are moving in different directions. Higher total revenue and net income may support investor confidence, but continued weakness in Device Solutions could limit growth if Patient Services does not keep expanding.

Analyst inference

The results show modest overall revenue growth alongside a sharper split between business lines. Gross profit rose 4% and the gross margin, meaning the share of revenue left after direct costs, increased to 58%; these figures suggest improved profitability despite Device Solutions’ decline.

Analyst inference

What to watch

1. Track whether Patient Services revenue growth continues and whether it can offset further declines in Device Solutions, since the segments contributed opposite trends this quarter. Analyst inference
2. Watch future reports for management’s explanation of the previously announced GE Healthcare contract restructuring and its effect on reported results; the supplied excerpt ends before giving details. Confirmed
3. Compare revenue growth with net income and adjusted EBITDA, a company-defined profit measure before interest, taxes, depreciation, and amortization, to see whether earnings keep improving. Analyst inference

Evidence

• Original source link unavailable